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ABSTRACT 
 
 “Neuropathologic study of a transgenic mouse model of Machado-Joseph 
disease” 
Machado-Joseph Disease (MJD) is an autosomal dominant neurodegenerative 
disorder caused by an expansion of the polyglutamine tract near the C-terminus of the 
ATXN3 gene product, ataxin-3 protein. Clinically, MJD is a very heterogeneous 
disorder, being the most common symptoms ataxia, loss of balance and coordination, 
and spasticity. The mutant ataxin-3 forms intranuclear and axonal aggregates in the 
brain cells of MJD patients. The remarkable degree of brain atrophy observed post-
mortem in brains of patients with this disorder as well as in other polyQ diseases would 
suggest that neuronal cell loss is a major feature of the pathogenic process. In order to 
understand if and how the expanded form of the gene causes cell demise in specific 
populations of neurons we performed stereological analysis, in order to determine the 
volumes and the number of cells in specific brain regions (known to be affected in MJD 
patients) in a transgenic mouse model of the disease. CMVMJD135 mice express 
ataxin-3 with 135 glutamines under the control of the CMV (cytomegalovirus) promoter 
and manifest MJD-like motor symptoms including balance deficit, gait ataxia and motor 
uncoordination that gradually appear and progress overtime, in the absence of premature 
death. They also show ataxin-3-positive intranuclear inclusions in several brain regions, 
namely in the pontine and dentate nuclei.  
 We found a decrease in the volume and total cell number in pontine nuclei and 
reduction of volume in dentate nuclei, with no differences in the total cell number. No 
differences were found in volume and total cell number in locus coeruleus and in 
substantia nigra; however, we observed a decrease of the number of dopaminergic 
neurons in substantia nigra pars compacta. In the cerebellum, we observed a reduction 
of molecular layer thickness. All together, these findings allow us to conclude that 
CMVMJD135 mouse is a promising model to study neurodegeneration in MJD, as it 
reproduces the specific neuronal loss observed in patients in a late stage of the disease. 
With this work we have identified possible quantitative biomarkers that could be very 
usefull in future pre-clinical trials with this model. 
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RESUMO 
 
  “Estudo neuropatológico num modelo de ratinho transgénico da doença de 
Machado- Joseph” 
 A Doença de Machado-Joseph (DMJ) é uma doença neurodegenerativa 
autossómica dominante causada por uma expansão anormal de repetições do 
trinucleótido CAG no gene ATXN3. Clinicamente, a DMJ é bastante heterogénea, 
constituindo os sintomas mais comuns a ataxia, perda de equilíbrio e de coordenação e 
espasticidade. A ataxina-3 expandida forma agregados intranucleares e axonais nos 
neurónios de doentes de Machado-Joseph. A atrofia observada em cérebros de pacientes 
post-mortem, bem como em outras doenças provocadas por expansão de glutaminas, 
sugere como característica chave do processo patogénico a morte neuronal. De modo a 
compreender como a forma expandida da proteína ataxina-3 afeta determinadas 
populações neuronais, foi realizada uma análise estereológica, de modo a determinar o 
volume e número total de células em regiões específicas do cérebro, descritas como 
afetadas na DMJ, num modelo da doença em ratinho. O ratinho transgénico 
CMVMJD135 expressa a proteína ataxina-3 com 135 glutaminas sob o controlo do 
promotor CMV (citomegalovirus) e manifesta sintomas motores característicos da DMJ 
que incluem perda de equilíbrio, ataxia e falta de coordenação motora que gradualmente 
progridem ao longo do tempo, na ausência de morte prematura. Apresenta ainda 
inclusões intranucleares de ataxina-3 em várias regiões do cérebro, tais como núcleos 
pônticos e denteados. Os resultados deste trabalho mostram uma redução do volume e 
do número total de células nos núcleos pônticos e uma redução do volume dos núcleos 
denteados que não é acompanhada por redução do número total de células. Não foram 
encontradas diferenças no volume e no número de total de células no locus coeruleus e 
na substantia nigra; no entanto, observamos uma diminuição do número de neurónios 
dopaminérgicos na substancia nigra pars compacta. Também verificámos uma redução 
da espessura da camada molecular do cerebelo. Em conjunto, estas descobertas 
permitem-nos concluir que o ratinho transgénico CMVMJD135 é um modelo promissor 
para estudar o processo de neurodegeneração na DMJ uma vez que ele reproduz a perda 
neuronal específica observada em doentes de Machado-Joseph. As alterações aqui 
identificadas constituem ainda biomarcadores possíveis de quantificação, de grande 
utilidade em futuros ensaios pré-clinicos usando este modelo animal. 
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1.1. Polyglutamine diseases - Overview  
 
 Polyglutamine diseases (PolyQ) are a large group of inherited neurodegenerative 
conditions. They are characterized by the pathologic expansion of CAG trinucleotide 
repeats in translated sequences of distinct genes (Bauer and Nukina, 2009). Currently, 
nine polyQ-related disorders are known: spinal bulbar muscular atrophy (SBMA), 
Huntington’s disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), and six 
types of spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17) (Zoghbi and Orr, 2000). They 
have different incidence rates, HD and SCA3, also known as Machado Joseph disease, 
being the most common (Schöls et al, 2004). 
 The CAG expansion leads to an abnormally long polyglutamine tract within 
proteins involved in the disease. A common feature of all polyQ disorders is the 
accumulation of mutant protein in the neuronal cells causing their dysfunction and 
eventually death (Bauer and Nukina, 2009). As represented in Table 1, for each polyQ 
disorder the subcellular localization of the aggregates in neurons can vary among 
nuclear and cytoplasmic inclusions. The number of CAG repeats in neurons can also 
vary. The expanded, longer than normal, polyglutamine repeats are unstable and tend to 
expand further in next generations. This leads to earlier age at onset and a more severe 
phenotype in successive generations - a phenomenon known as anticipation (Schöls et 
al, 2004). 
 Studies have investigated which structure of expanded polyglutamine is 
responsible for disease progression. The hypothesis that a toxic structure of expanded 
polyglutamine causes the disease explains its length-dependence and implies a common 
mechanism of pathogenesis in polyQ diseases, however it is not sufficient to explain the 
selective pattern of toxicity of these causative proteins that leads to different 
neuropathologic involvement and clinical manifestations (Takahashi et al, 2010). 
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Table 1. Pathogenic features of polyglutamine diseases (adapted from Ross, 1995; Seidel et 
al, 2012). 
 
 
 In spite of these commonalities, in most cases, the neuropathology of each 
polyQ disease is associated with a specific subset of neurons. However, it is not clear 
the relationship between expression pattern and pathology location, once the causative 
proteins are widely expressed in the Central Nervous System (CNS) as well as in 
peripheral tissues (Gusella and MacDonald, 2000), except for SCA6, where the gene 
product is expressed predominantly in Purkinje cells of the cerebellum (highly affected 
in SCA6) (Ishikawa et al, 1999) and in SBMA, where the androgen receptor is primarily 
expressed in the vulnerable motor neurons (reviewed in Costa and Paulson, 2012). 
 All of these polyQ disorders are dominantly inherited in an autosomal manner 
with the exception of SBMA, which is X-linked and was the first disease connected 
with the expansion of CAG repeat causing progressive motor neuron degeneration (La 
Spada et al, 1991). Specific affected neuronal populations are still an important object 
Disease Causative gene CAG repeat size Agregates Brain regions atrophy 
  
Normal Disease 
  
HD HTT 6 to 35 36 to 121 Cytoplasmic 
 
Striatum and cerebrum 
cortex 
DRPLA ATN1 3 to 38 49 to 88 Cytoplasmic 
 
Pallidum, subthalamic, 
dentate nuclei and red 
nucleus 
SBMA AR 6 to 36 38 to 62 
Nuclear and 
cytoplasmic 
 
Anterior horn, bulbar 
neurons and dorsal route 
ganglia 
SCA1 ATX1 6 to 39 41 to 83 Nuclear Cerebellum and brainstem 
SCA2 ATX2 14 to 32 34 to 77 
Nuclear and 
cytoplasmic 
Cerebellum, pons, medulla 
oblongata and spinal cord 
SCA3/MJD ATXN3 12 to 40 62 to 86 
Nuclear and 
cytoplasmic 
Cerebellum, brainstem and 
spinal cord 
SCA6 CACNA1A 4 to 18 21 to 30 Cytoplasmic Cerebellum and brainstem 
SCA7 SCA7 7 to 18 38 to 200 Nuclear Cerebellum and brainstem 
SCA17 TBP 25 to 43 45 to 63 Nuclear 
 
Cerebrum, cerebellum and 
brainstem 
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of study in these disorders because they differ among diseases and determine the 
characteristic clinical symptoms associated with each disorder. For instance, HD 
patients show neurodegeneration in the striatum leading to uncontrolled movements 
whereas in SCAs cell loss occurs mainly in the cerebellum, causing ataxia (table 2). 
 
Table 2. Clinical features of polyglutamine diseases (adapted from Takahashi et al, 2010). 
 
XR, X-linked recessive; AD, autosomal dominant. 
 
 The role of the aggregation in disease pathogenesis is not clear. It is 
controversial whether the toxicity of the expanded polyQ proteins results from the 
presence of visible aggregates or from smaller intermediary species generated during 
the aggregation process. Aggregates may just represent end products of the upstream 
toxic event (Bauer and Nukina, 2009). Some studies have suggested that the inclusions 
have a protective role (Saudou et al, 1998). Several issues have been studied regarding 
pathogenesis of polyglutamines: i) whether the specific structure of expanded 
polyglutamine results in toxicity to cells; ii) the type of dysfunction that leads to disease 
as well as iii) how the expanded polyglutamine protein causes dysfunction (Takahashi 
et al, 2010). 
Until now, there is no effective therapy preventing the physical (and in some 
polyQ diseases also mental) decline caused by the dysfunction and eventually death of 
neurons in these disorders, aggravated by the accumulation of mutant proteins inside 
neurons (Bauer and Nukina, 2009). 
 
 
 
Disease Inheritance Clinical features 
SBMA XR Weakness, bulbar symptom, fasciculations, tremors, gynecomastia. 
HD AD Chorea, dystonia, dementia. 
DRPLA AD Myoclonus epilepsy, ataxia, chorea, dementia. 
SCA1 AD 
Ataxia, bulbar symptom, spasticity, polyneuropathy, cognitive 
impairment. 
SCA2 AD Ataxia, slow saccades, ataxia, polyneuropathy, parkinsonism. 
SCA3 AD Ataxia, spasticity, polyneuropathy, diplopia, dystonia. 
SCA6 AD Ataxia, dysarthria, down-beating nystagmus. 
SCA7 AD Ataxia, retinal degeneration, ophthalmoplegia. 
SCA17 AD Ataxia, dementia, psychosis, seizures, extrapyramidal signs. 
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1.2. MJD – Machado-Joseph disease  
  
 Machado-Joseph disease was first studied in 1972 by Nakano and co-workers. 
They characterized this disease as a hereditary ataxia in Portuguese emigrants to 
Massachusetts. They studied the first family affected by a progressive cerebellar 
degeneration transmitted in autosomal dominant manner and named this disorder as 
Machado disease (Nakano et al, 1972). In the same year, Woods and Schaumburg 
reported a study in other family, also from Azores Islands and established in 
Massachusetts, that presented similar clinical symptoms; They characterized the disease 
as an autosomic dominant disorder, however they named it as “nigrospinodentatal 
degeneration with nuclear ophthalmoplegia” (Woods and Schaumburg, 1972). In 1976, 
a separate entity was reported in an Azorean family, the Joseph family, emigrated to 
California; Researchers classified the disorder as an autosomal dominant striatonigral 
degeneration and called it as “Joseph disease” (Rosenberg et al, 1976).  One year later, 
the fourth family was studied and the disease was this time described as “Azorean 
disease of the nervous system” (Romanul et al, 1977). In 1978, Coutinho and Andrade 
studied 40 patients from 15 families affected by an autosomal dominant late onset 
genetic disorder from the Azorean Islands and reported that this genetic disease had 
variable phenotypic patterns, which were variations of the same disorder, proposing the 
name of Machado-Joseph disease. They classified the clinical features of the disease in 
three main types in order to comprise the different patterns of neuropathology observed 
until then in MJD patients (Coutinho and Andrade, 1978).  
  Presently, MJD, also called spinocerebellar ataxia type 3 (SCA3), is known to 
be the most common dominantly inherited ataxia worldwide (15- 45% of all forms in 
different countries and ethnic populations) (Paulson, 2007). 
 MJD is caused by the expansion of CAG repeat in the ATXN3 gene causing an 
extension of a polyglutamine repeat in the C-terminus of the gene protein product 
ataxin-3 (Kawaguchi et al, 1994). In normal individuals ataxin-3 contains between 12 
and 40 glutamines, whereas most of the clinically diagnosed MJD patients show 
expansion of the repeat-number from 60 to 84 (Paulson et al, 2000).  
CAG expansion has a dynamic behaviour, which reflects on the general 
tendency of expanded repeats to become larger when transmitted to next generation. 
Nevertheless, there is a differential instability of the CAG tract length between male and 
female transmissions. Repeat instability appears to be more frequent when transmission 
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occurs through a male than through a female (Maciel et al, 1995).This dynamic feature 
of the disease mutation explains the phenomenon of anticipation observed in some MJD 
families, in which affected offspring tend to manifest disease earlier than an affected 
parent (Sequeiros and Coutinho, 1993). In MJD, CAG repeat instability can also occur 
in different cells from the same tissue, a phenomenon known as somatic mosaicism 
(Maciel et al, 1997). 
 
1.2.1. Epidemiology and Clinical features 
 
MJD is presently considered the most common form of SCA worldwide, with 
families described in Portugal, Spain, Singapore, the Netherlands, Germany, Italy, the 
Czech Republic, United States, Canada, Brazil, Mexico, China, Japan, India and 
Australia. The relative frequency of MJD is higher in countries such as Brazil (69-92%) 
and Portugal (58-74%) with high prevalence in the Azores Islands, namely Flores Island 
(1/239) (Bettencourt and Lima, 2011). In contrast, MJD is almost absent in Italy and in 
the Czech Republic (Bauer and Nukina, 2009). 
MJD symptoms begin to manifest by the age of 30-50 years, usually culminating 
in early death (on average 20 years after the onset of disease). The symptoms of this 
polyQ disorder comprise cerebellar ataxia, peripheral nerve palsy, pyramidal and 
extrapyramidal features (Rosenberg, 1992). There are other specific characteristics that 
can be of major importance for the clinical diagnosis of MJD such as external 
progressive ophthalmoplegia, dystonia, intention fasciculation-like movements of facial 
and lingual muscles, as well as lid retraction, originating the aspect of “bulging eyes”. 
MJD encompasses a wide high clinical spectrum and it can be divided in four different 
phenotypes: type I corresponds to an early onset (10 to 30 years) which is characterized 
by extrapyramidal (mainly dystonic) and pyramidal deficits; type II has an intermediate 
onset, it appears between 20 and 50 years and is marked by pyramidal and cerebellar 
deficits; type III is featured by a late onset (40 to 75 years) emerging with cerebellar 
deficits and peripheral neuropathy (Coutinho and Andrade, 1978). Finally, type IV is 
the rarest and is characterized by uncertain onset, arising with neuropathy and 
parkinsonism (Rosenberg, 1992).   
 Although no cure or treatment for this disease has been discovered yet, 
symptomatic treatment can relieve some symptoms caused by the disease. Spasticity 
can be efficiently treated with baclofen, tizanidine or memantine combined with 
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dopaminergic treatment (Riess et al, 2008). Amantadine and small dosages of botulinum 
toxin can be beneficial for dystonia (Woods and Schaumburg, 1972) and muscle cramps 
can be ameliorated with magnesium, mexiletine and chinine (Kanai et al, 2003). 
Dopaminergic treatment is the long lasting therapy for Parkinsionism symptoms 
(Buhmann et al, 2003). Besides, daily training of gait and physiotherapy can also help to 
meliorate ataxia symptoms. Logopedic treatment is good for dysarthria and dysphagia 
in order to maintain the ability to communicate and to prevent pneumonia from 
aspiration. Nevertheless, the efficacy of these approaches decreases with time and 
eventually the disease progression is unavoidable (Riess et al, 2008).  
 
1.2.2. Neuropathology 
 
MJD affects a large variety of functional and neurotransmitter systems and it 
results in a central nervous distribution pattern of lesions that is widespread and severe 
(Seidel et al, 2012). 
 Magnetic resonance spectroscopy analysis of deep white matter has shown 
metabolic abnormalities suggestive of axonal dysfunction in MJD patients (D'Abreu et 
al, 2009). Positron emission tomography studies on the regional cerebral glucose 
metabolism revealed a significantly decreased glucose utilization in the cerebellum, 
brainstem, striatum and whole cerebral cortex (Taniwaki et al, 1997). Moreover, 
decreased binding for DAT (Dopamine transporter) in these regions was observed in 
symptomatic MJD patients (Wüllner et al, 2005). 
Enlargement of the fourth ventricle is the most consistent feature observed by 
magnetic resonance imaging (MRI) in MJD patients. Furthermore, the neuropathology 
of MJD includes severe neuronal loss in the anterior horn and Clarke’s column of the 
spinal cord (table 3) and in restricted brain regions such as dentate nucleus (cerebellum), 
pontine nuclei and locus coeruleus (brainstem), substantia nigra (basal ganglia) and 
other regions such as the thalamus, as well as subthalamic, red and cranial nerve nuclei 
(Romanul et al, 1977). It is also characterized by axonal neuropathy of peripheral motor 
and sensory axons (Klockgether et al, 1999). 
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Table 3. Mean cross sectional area (upper spinal cord) in SCA3 and controls 
(adapted from Lukas et al, 2008). 
 
 
In MJD, the atrophy in the cerebellum and brainstem (figure 1) is progressive 
and dependent on the length of the CAG repeat and the age of the patients (Eichler et al, 
2011). However, different brain regions present different rates of atrophy and 
progression. While atrophy of the cerebellum and pontine base seem to correlate with 
patient’s age, atrophy of the midbrain and pontine tegmentum show no significant 
progression in longitudinal studies by MRI with observation periods of 4.5–10.6 years, 
compatible with very slow evolution of pathology in these regions (Horimoto et al, 
2008). 
 
 
Figure 1. Sagittal T1-weighted images of the brainstem and cerebellum in patients with SCA3 
and in a healthy control subject (adapted from Eichler et al, 2011). 
 
Upon macroscopic examination, the brains of MJD patients with a disease 
duration of more than 15 years showed a depigmentation of the substantia nigra, a 
considerable atrophy of the cerebellum, pons, and medulla oblongata; an atrophy of the 
cranial nerves III to XII were also consistently observed (Rüb et al, 2008). In addition, 
in the majority of these MJD patients, the total brain weight was lower than that of 
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individuals without medical histories of neurological or psychiatric diseases, which by 
itself is an indicator of brain atrophy in patients (Bürk et al, 1996). In contrast to 
previous conventional neuropathological studies, recent pathoanatomical studies 
involving unconventional serial thick tissue sections demonstrated a more extensive 
damage affecting areas of the cerebellothalamocortical motor loop, the basal ganglia-
thalamocortical motor loop, and several other systems: visual, auditory, somatosensory, 
vestibular, oculomotor, ingestion-related brainstem nuclei, precerebellar brainstem, 
cholinergic and dopaminergic midbrain, and pontine noradrenergic systems (table 4) 
(Rüb et al, 2008).  
 
Table 4. Summary of the CNS components that undergo neurodegeneration during the 
course of MJD (Rüb et al, 2008). 
Affected central nervous component  Major lesions 
Cerebellothalamocortical motor loop  
Cerebellar cortex, dentate and fastigial nuclei; pontine nuclei; 
thalamic ventral lateral nucleus;giant Betz pyramidal cells of the 
primary motor cortex; anterior horn motoneurons of the spinal 
cord 
Basal ganglia–thalamocortical motor loop 
Pallidum; subthalamic nucleus; thalamic ventral lateral and 
reticular nuclei 
Visual system  
Lateral and inferior nuclei of the pulvinar; lateral geniculate body 
of the thalamus 
Auditory system  
Inferior colliculus; nuclei of the lateral lemniscus; superior olive; 
cochlear nuclei 
Somatosensory system  
All somatosensory nuclei of the thalamus, pons and medulla 
oblongata; Clarke’s column of the spinal cord 
Vestibular system  Superior, lateral, medial, spinal and interstitial vestibular nuclei 
Oculomotor system 
 Oculomotor, trochlear, and abducens nuclei; rostral interstitial 
nucleus of the medial longitudinal fascicle;reticulotegmental 
nucleus of the pons; area of the excitatory burst neurons for 
horizontal saccades;raphe interpositus nucleus; prepositus 
hypoglossal nucleus 
Ingestion-related brainstem system  
All somatosensory, somatomotor, viscerosensory and 
visceromotor ingestion-related brainstem nuclei;ingestion-related 
regions of the brainstem reticular formation 
Precerebellar brainstem system 
Arcuate nucleus; red nucleus; pontine nuclei; reticulotegmental 
nucleus of the pons; vestibular nuclei;lateral reticular nucleus; 
external cuneate nucleus; prepositus hypoglossal nucleus; dorsal 
paramedian reticular nucleus; nucleus Roller; inferior olive 
Midbrain dopaminergic system  
Mesostriatal dopaminergic system (substantia nigra); mesolimbic 
dopaminergic system (nuclei of the ventral tegmental area) 
Midbrain colinergic system  Pedunculopontine nucleus 
Pontine noradrenergic system Locus coeruleus 
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Furthermore, these recent studies revealing that the widespread damage of 
cerebellum, thalamus, midbrain, pons, medulla oblongata, and spinal cord in MJD is 
comparable to that commonly seen in terminal SCA2 and SCA7 patients, provide 
suitable explanations for a variety of less understood clinical MJD symptoms (Riess et 
al, 2008). 
 
1.2.3. Cell death  
 
- In MJD patients 
 
 The mechanism of cell death in polyQ diseases remains unclear and might be 
very complex, as many processes triggered by the presence of expanded polyQ proteins 
can lead to cell death.  This phenomenon can be due such as direct activation of cell 
death pathways, mitochondrial abnormalities, transcriptional dysregulation, proteasome 
impairment, defects in axonal transport, or unfolded protein response. Other 
pathophysiological events such as those associated with excitotoxicity, metabolic stress, 
or accumulation of free radicals may promote the cell fate toward death by further 
enhancing the mitochondrial dysfunction (Bauer and Nukina, 2009) 
 Apoptosis has been proposed as a possible mechanism for neuronal death in 
neurodegenerative diseases (Ekshyyan and Aw, 2004). However, there is no direct and 
convincing evidence of apoptosis in brains of patients with these disorders, and the 
mechanisms of neuronal death in most neurodegenerative diseases remain unknown. 
The mechanisms of pathogenesis in MJD have not been fully clarified. Several lines of 
evidence have suggested that the apoptotic machinery can be triggered by the expansion 
of polyglutamine stretches which MJD mutant protein contains (Ikeda et al,1996). 
Based on that, Kumada and co-workers examined the occurrence of apoptotic cell death 
using terminal deoxynucleotidyl-transferase (TdT)-mediated in situ nick end labelling 
(TUNEL) assay in brains obtained at autopsy from MJD patients, and 
immunohistochemically investigated the in situ expression of apoptosis-related proteins. 
These authors found an augmentation of Bcl-x (Bcl-xS and Bcl-xL) expression, well 
known apoptosis-related proteins in the Purkinje cells of three cases (Kumada et al, 
2000). However they found this result intriguing once Bcl-xS is a proapoptotic protein 
and Bcl-xL is a well characterized antiapoptotic protein. Nervetheless, more recent 
studies demonstrated that expression ataxin-3-Q79 in cultured CNS rat neurons causes 
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an upregulation of Bax mRNA level and downregulation of Bcl-xL mRNA levels (Chou 
et al, 2006). One case of MJD showed TUNEL-positive granular cells in the cerebellar 
cortex (Kumada et al, 2000).  
 The upregulation of inflammatory genes in cell lines expressing expanded 
ATXN3 was confirmed by detection of neuroinflammatory markers in the pons of MJD 
patients, suggesting that glia contribute to MJD pathogenesis (Evert et al, 2001). The 
precise role of glia in the pathogenic mechanism of MJD is largely unexplored. 
However, studies in a transgenic mouse model for MJD in 2010, reported that glial cells 
were not primed for activation before the onset or in early stages of the disease, 
suggesting that glial activation observed in post-mortem tissues could be a consequence 
rather than a cause of a long neurodegeneration process undergone by human patients 
(Silva-Fernandes et al, 2010). Systematic temporal and functional analysis of the several 
types of glial cells in brains from MJD patients and MJD mouse models will help to 
understand their specific role during the development of this disease. 
- In mouse models of MJD 
  
 Some mouse models of MJD developed so far demonstrated neurodegeneration 
of specific affected regions overlapping those affected in human MJD patients. 
Moreover, despite several MJD mouse models having been generated, only some of 
them demonstrated neurodegeneration in specific regions of the brain (table 5). The first 
transgenic mouse model of MJD expressing truncated cDNA of the ATXN3 gene under 
the control of the L7 promoter of Purkinje cells showed an atrophic cerebellum and 
massive loss of Purkinje cells, which are not primarily affected in MJD (Ikeda et al, 
1996). In 2002, pathological examination of the brains of YAC-transgenic mice 
carrying the full genomic region of the ATXN3 gene with expanded (CAG)n alleles 
showed degeneration and mild gliosis of the dentate and pontine nerve nuclei. These 
findings were consistent with the pathological findings reported in MJD patients, where 
the degeneration of these regions also involves neuronal loss and gliosis. Surprisingly, 
immunostaining against the astrocytic marker GFAP confirmed the presence of 
increased numbers of reactive astrocytes also in the cerebellar white matter of 
symptomatic mice. There was atrophy of the cerebellar Purkinje and molecular cell 
layers, which was influenced by CAG repeat length and gene dosage (Cemal et al, 
2002). In 2004, a transgenic mouse model expressing human mutant (Q71) ataxin-3 
under the control of the mouse prion promoter demonstrated a 38% decrease of 
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dopaminergic neurons (tyrosine hydroxylase [TH]-positive neurons) in the substantia 
nigra, a region which is also affected in humans. Other brain areas which develop 
neuronal cell loss in human MJD patients such as the spinal cord, dentate nuclei, 
pontine nuclei, and to a lesser degree the cerebellar cortex were not altered in this 
mouse model (Goti et al, 2004). Degenerated Purkinje cells are also observed in human 
SCA3 patients (Muñoz et al, 2002); in 2010, other mouse model of SCA3 was 
generated expressing ataxin-3 with 148 CAG repeats under the control of the huntingtin 
promoter and the authors observed using electron microscopy, darkly stained Purkinje 
cells, considered as a sign for degeneration in this mouse model at 20 weeks of age 
(Boy et al, 2010). However, this finding is a little controversial once many 
neuropathologists consider dark neurons as the most common histologic artefacts 
(Jortner, 2006). Also in 2010, Silva-Fernandes and co-workers at our lab developed a 
mouse model of MJD expressing the ataxin with 94 CAG under the control of the CMV 
promoter and observed neuronal atrophy in the pontine and dentate nuclei and 
astrogliosis in the vestibular nuclei and substantia nigra. However, and in spite of its 
neurological phenotype, no cell death (apoptosis or necrosis) and no signals of 
microglial activation or neuroinflammatory response were observed in the brains of this 
transgenic mouse (Silva-Fernandes et al, 2010). 
  
Table 5. Neuronal loss observed in MJD mouse models (adapted from  Ikeda et al, 1996; 
Cemal et al, 2002; Goti et al, 2004; Bichelmeier et al, 2007; Silva-Fernandes et al, 2010). 
Mouse 
models 
Neurodegeneration 
Use of 
unbiased 
stereology 
Q79-C Atrophic cerebellum (H&E staining) and massive Purkinje cell loss (IHC anti calbindin) No 
MJD84.2 
Decrease in pontine and dentate nuclei neurons (H&E staining) 
No 
Purkinje cell loss marked by observations of empty baskets  (IHC anti-Calbindin) 
Inscreased number of glial cells in dentate nucleus and cerebellar white matter (IHC 
anti-GFAP) 
Homozygous 
Q71C 
38% fewer (TH)-positive neurons in substantia nigra (IHC anti-TH) 
Yes No statistically significant differences were found in the total number of neurons in 
dentate nucleus (Nissl staining) 
70.61 
Empty baskets around Purkinje cells indicative of Purkinje cell loss  (IHC anti-
phosphorylated neurofilament) 
No 
CMVMJD94 Increased number of glial cells in substantia nigra e vestibular nuclei (IHC anti-GFAP) Yes 
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 For the mouse models of MJD generated so far, stereological characterization of 
the brain has not been extensively performed. Goti and co-workers performed unbiased 
stereology in order to quantify the specific neuronal loss and show that the homozygous 
Q71C mice showed 38% fewer (TH)-positive neurons in the substantia nigra (Goti et al, 
2004). Also in hemizygous-CMVMJD94 mice, unbiased stereology was performed to 
quantify GFAP-positive cells in the substantia nigra and in the vestibular nuclei, where 
an increased number of glial cells was found (Silva-Fernandes et al, 2010).  
  
 In summary, the mechanisms that cause selective neurodegeneration in MJD are 
poorly understood and until the moment no model has yet successfully reproduced the 
specific neuronal loss observed in humans. Indeed, some transgenic mouse models 
developed motor symptoms in the absence of neuronal cell death (Bichelmeier et al, 
2007; Silva-Fernandes et al, 2010). This fact is in agreement with the slow progression 
of polyQ disorders, in which it is unlikely that neuronal cell death could be the 
responsible for symptoms early in the course of disease; instead, it could be a final stage 
after a long period of neuronal dysfunction. 
 
 1.2.4. Genetics  
 
In 1993, the MJD locus was mapped in the long arm of chromosome 14 
(14q24.3-q32) (Takiyama et al, 1993). One year later, it was found that expansion of 
CAG repeat motif at the MJD1 gene, mapped on the long arm of chromosome 14 was 
present in all affected people of a pathologically confirmed MJD family. In 2001, it was 
discovered that MJD1 gene spanned around 48 kb and contained 11 exons, the CAG 
stretch being located in the exon 10 (Figure 2) (Ichikawa et al, 2001). Nowadays, the 
official symbol for this gene is ATXN3, although MJD and MJD1 are still commonly 
used (Bettencourt and Lima, 2011). 
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Figure 2. Representation of ATXN3 gene structure. Exons are numbered from 1 to 11.  Blue 
boxes indicate translated regions; horizontal boxes represent the 5’-untranslated region (UTR) 
and diagonal boxes correspond to the 3’-UTR. The location of the polymorphic (CAG)n tract is 
indicated (Bettencourt and Lima, 2011). 
 
 ATXN3 is ubiquitously expressed in the CNS and in the peripheral tissues 
(Trottier et al, 1998). Low levels of ATXN3 mRNA are also present in glial cells 
(Nishiyama et al, 1996). Neurons susceptible to cell death in MJD patients do express 
ATXN3, although not selectively. The cellular ATXN3 mRNA level does not correlate 
with clinical severity or pathological involvement. Expression levels of CAG repeats in 
MJD patients and normal controls do not differ, indicating that the pathogenesis of MJD 
may involve direct toxicity to vulnerable subsets and/or region-specific co-factors of 
MJD proteins (Nishiyama et al, 1996). 
 
 1.2.5. Ataxin-3 
 
In normal individuals, ataxin-3 has an approximate molecular weight of 42 kDa. 
However, it is significantly larger in MJD patients, since the elongation of CAG repeat 
results into an expanded polyQ stretch. This polyQ tract is located in the C-terminus 
region of the protein, that is variable in length, depending on the isoform (Kawaguchi et 
al, 1994). 
Ataxin-3 is an ubiquitin-binding protein with ubiquitin hydrolase activity in vitro 
(Burnett et al, 2003), proposed to be related with ubiquitin proteosome pathway (UPS) 
and with transcription regulation. This mutant protein is expressed in neuronal and non-
neuronal tissues and when the polyglutamine sequence is expanded it tends to aggregate 
within cells forming neuronal nuclear inclusion bodies (NNIs). NNIs are frequently 
observed in brain tissue of MJD patients and are regarded as an important 
morphological hallmark of the neurodegeneration process in animal models (Paulson et 
1. INTRODUCTION 
 
16 
 
al, 1997; Seidel et al, 2010). NNIs are ubiquitinated and contain other proteins, namely 
members of the quality control systems, such as proteosome constituents, ubiquitin and 
molecular chaperones, as well as transcription factors. The precise role of NNIs on the 
neurodegeneration that occurs in MJD remains unknown (reviewed in Seidel et al, 
2010). This fact restricts our understanding of the mechanisms by which the mutated 
protein leads to the selective neuronal death profile. However, since NNIs are present in 
degenerated as well as spared regions of the brain of patients with advanced MJD, NNIs 
are not thought to be directly pathogenic in affected nerve cells (Arrasate et al, 2004; 
Rüb et al, 2006). 
Recent studies have shown that neuronal demise may be caused by gain of a 
toxic function of the monomeric mutant ataxin-3, by the partial loss of ataxin-3 function 
and/or by the toxic effects of soluble amyloid-like oligomers formed by the aggregation 
of the protein (Matos et al, 2011).  However, further knowledge about ataxin-3 biology, 
the way that it functions, as well about the role it plays in normal cell physiology is 
much needed. 
 
1.2.6. Mouse models 
 
The identification of the disease causative gene ATXN3 has made possible the 
development of animal models for use in studying the mechanisms of pathogenesis of 
MJD. Mice are the preferred animal model because they are small, short-lived and can 
be generated in relatively large numbers, kept in a controlled environment, and be used 
for invasive procedures. Being mammals, they have important genomic, anatomical and 
physiologic similarities to humans. The problems encountered in the use of patient brain 
tissue, such as autolysis caused by long post-mortem delays and possible effects of 
hypoxia or inflammation associated with the immediate causes of death (in MJD, most 
often respiratory failure due to immobility-associated respiratory tract infections) rather 
than by the neurological disease process itself can be avoided using mouse models 
(Colomer, 2005). 
Animal models of MJD have been established in order to study the molecular 
pathway(s) involved in the process of neurodegeneration (table 6) as well as for the 
assessment of pre-clinical therapeutic trials.  The first transgenic mouse model of MJD 
was generated expressing truncated and full-length cDNA of the ATXN3 gene under the 
control of the L7 promoter of Purkinje cells (poorly affected in MJD). No ataxic 
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phenotype was observed at 23 weeks of age in animals expressing the full-length ataxin-
3 with 79Q whereas animals expressing the polyQ fragment displayed an ataxic 
behaviour at 4 weeks of age and presented an atrophic cerebellum and massive loss of 
Purkinje cells.  This work showed that the expanded polyglutamine tract is per se 
responsible for neuronal loss and degeneration (Ikeda et al, 1996).  
In 2002, Cemal and co-workers generated transgenic mouse models using the 
yeast artificial chromosome (YAC) containing the full-length human MJD1 gene coding 
for all alternative spliced isoform of mutant ataxin-3, with 64 to 84 CAG repeats, under 
the control of the endogenous MJD1 promoter. These mice with expanded alleles 
demonstrated a mild and slowly progressive cerebellar deficit, manifesting the 
symptoms at 4 weeks of age. As the disease progressed, pelvic elevation became 
markedly flattened, accompanied by hypotonia, and motor and sensory loss. NII 
formation and cell loss was prominent in the pontine and dentate nuclei, with variable 
cell loss in other regions of the cerebellum from 4 weeks of age; animals also displayed 
peripheral nerve demyelination and axonal loss at 26 weeks of age. This mouse was the 
first model described expressing the full-length MJD1 gene under the control of its own 
regulatory elements. However, the phenotype that these mice exhibited was considered 
too mild for use in therapeutic trials (Cemal et al, 2002).  
In 2004, another transgenic mouse model was generated expressing human 
mutant (Q71) ataxin-3 under the control of the mouse prion promoter. Q71 transgenic 
mice expressing mutant ataxin-3 above a critical level developed a phenotype including 
progressive postural instability, gait and limb ataxia, weight loss, premature death, 
neuronal intranuclear inclusions, and decreased tyrosine hydroxylase-positive neurons 
in the substantia nigra. Interestingly, a C-terminal cleavage fragment of the transgene 
product has been revealed in this model, which the researchers also observed in human 
patients’ post-mortem brains (Goti et al, 2004).  
Three years later, Bichelmeier and co-worker generated a new transgenic mouse 
for SCA3 using full-length ataxin-3 cDNA constructs containing 15, 70 and 148 CAG 
repeats, expressed under the regulation of the mouse prion promoter. Transgenic mice 
of ataxin-3 with expanded polyglutamine repeats were severely affected by a strong 
neurological phenotype with tremor and wide-based hindlimbs, as well as markedly 
reduced motor and exploratory activity, a hunchback, and premature death at 3 to 6 
months of age. Q148 mice displayed a more severe neurological phenotype with more 
inclusions and earlier death when compared with mice expressing mutant ataxin-3 with 
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70 CAG repeats. The authors proved that the nuclear localization of the mutant protein 
is crucial for pathogenesis to occur, by the manipulation of the ataxin-3 cellular 
localization with a NLS (Nuclear Localization Signal) or NES (Nuclear Export Signal) 
(Bichelmeier et al, 2007). 
In 2008, a transgenic mouse model was developed expressing human 
polyglutamine-expanded ataxin-3-Q79 under the mouse prion promoter. Ataxin-3-Q79 
was expressed in cerebellum, pontine nucleus and substantia nigra. Ataxin-3-Q79 
transgenic mice displayed motor dysfunction with an onset age of 5-6 months, and 
neurological symptoms deteriorated in the following months. Prominent neuronal loss 
was not found in the cerebellum of 10 to 11-month-old ataxin-3-Q79 mice displaying 
pronounced ataxic symptoms, suggesting that instead of neuronal death, ataxin-3-Q79 
caused neuronal dysfunction in the cerebellum and ataxia by disrupting the normal 
pattern of gene transcription (Chou et al, 2008).  
In 2010, Boy and co-workers generated a mouse model of SCA3 expressing 
ataxin-3 with 148 CAG repeats under the control of the huntingtin promoter, resulting 
in ubiquitous expression throughout the whole brain. The model showed many features 
of the disease, including a late onset of symptoms and CAG repeat instability in 
transmission to offspring. They observed hyperactivity during the first months (not 
observed in MJD patients) and decline of motor coordination after about 1 year of age. 
Few and small intranuclear aggregates appeared first at the age of 18 months, further 
supporting that neuronal dysfunction precedes the formation of intranuclear aggregates 
(Boy et al, 2010). 
 In 2010, our group developed a mouse model for MJD expressing the isoform 
ataxin-3c with 94 CAG under the control of the CMV promoter, resulting in a 
widespread expression. The model showed reduced balance and coordination, and a 
very mild locomotor hypoactivity. This mouse model showed intergenerational 
instability of the CAG repeat and a tissue-specific increase in the somatic mosaicism of 
the repeat with aging. Histopathological analysis of these MJD mice at early and late 
stages of the disease revealed neuronal atrophy and astrogliosis in several brain regions 
(Silva-Fernandes et al, 2010). 
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Table 6.  Brain Pathology of the Mouse Models for MJD (adapted from Colomer, 2012). 
 
 
 
 
*Neuronal intranuclear inclusions detected in pons, cerebellar nuclei, substantia nigra, and/or Purkinje cells. Evidence of neurodegeneration reported as: a) decrease in number of neurons of 
pons, dentate nuclei, substantia nigra, and/or Purkinje cells stained with dye or antibody; b) Increase in number of glial cells immunostained in pons, dentate nuclei, substantia nigra, and/or the 
rest of cerebellum; and c) abnormal morphology of neurons in pons, dentate nuclei, substantia nigra, and/or Purkinje cells. They are included as present (Yes), absent (No), not reported (NR), or 
not determined (ND). Severity of pathology (last column) is based on whether neuronal intranuclear inclusions (NI) and/or any evidence of neurodegeneration (ND) were detected. 
 
*Only reported in Purkinje cells.
Mouse model 
reference 
Severity of behaviour 
Intranuclear 
inclusions in 
neurons (NI) 
Neurodegeneration 
  
 
Severity of 
pathology 
Decrease in number of neurons 
dyed or immuno stained 
 
Increase in number 
of glial cells immuno 
stained  
Abnormal 
morphology 
Ikeda et al, 1996 High ND ND ND   Yes* Intermediate 
Cemal et al, 2002 Intermediate Yes Yes  Yes Yes Intermediate 
Goti et al, 2004 High Yes Yes  ND ND High 
Bichelmeier et al, 2007 High Yes Yes  NR Yes High 
Chou et al, 2008 Intermediate Yes No NR Yes Intermediate 
Boy et al, 2010 Low Yes NR NR Yes Low 
Silva-Fernandes et al, 
2010 
Low No NR Yes Yes Low 
Silva-Fernandes et al, 
(submitted for 
publication) 
Intermediate Yes Yes  ND Yes Intermediate 
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 Various mouse models have been generated using methods such as the induction 
of highly expanded polyglutamine tracts, an increase of transgene copy number, and the 
use of specific promoters. These mouse models indicate that the CAG repeat length, 
which is responsible for MJD in humans, is not sufficient for creating the equivalent 
disease conditions in mice. In order to mimic selective neuronal degeneration of CAG 
repeat diseases in mice, it may be necessary to express a much higher level of mutant 
protein with a proper spatio-temporal pattern in the brain. The short lifespan of mice, or 
possibly high levels of metabolic activity directed against the mutant proteins may 
partly explain the fact that until now no model fully represents the neuropathologic 
changes observed in humans (Yamada et al, 2008). 
 
 
 1.2.7. A new mouse model: CMVMJD135 
 
 Recently, our group has generated a transgenic mouse model, CMVMJD135, 
expressing ataxin-3 carrying 135 glutamines under the control of the CMV promoter. 
With the increase of CAG repeats to 135 in the human ataxin-3 protein (ATXN3) 
expressed by transgenic animals (CMVMJD135), we have successfully established a 
mouse model carrying several neurological symptoms of MJD that appear gradually 
along the disease progression.  
 CMVMJD135 mice manifest MJD-like motor symptoms beginning at 6 weeks, 
when they present loss of limb strength, given by a significant decrease in the time in 
the hanging-wire-grip and in the vertical pole test. At 10 weeks of age, animals 
developed a balance deficit in the beam test and at 20 weeks of age they displayed 
motor uncoordination in the rotarod, in addition to tremors and limb clasping at 19 
weeks of age. Locomotor and exploratory activity was decreased in transgenic mice at 
this stage. At 12 weeks of age the gait analysis demonstrated that transgenic animals 
exhibited foot dragging and at more advanced ages, 16 weeks, swimming 
uncoordination and a shorted step (figure 3) (Silva-Fernandes et al, submitted for 
publication). 
 Histopathological observation of brain sections of transgenic CMVMJD135 
mice sacrificed at the age of 24 weeks revealed the presence of shrunken cells (violet 
cresyl staining) in several regions, such as the pontine nuclei, vestibular nuclei and 
substantia nigra in comparison with normal cells observed in wild-type animals. No 
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apoptotic cells were found in the affected brain areas of CMVMJD135 mice at this age 
by TUNEL assay. Autophagy, also an important process for degradation of protein 
aggregates was evaluated in the brainstem of CMVMJD135 and no alterations in the 
autophagy activation were found (Silva-Fernandes et al, submitted for publication).  
 Immunohistochemistry (IHC) with anti-ataxin-3 and ubiquitin antibodies 
showed the presence of inclusions in the nucleus of neurons in CMVMJD135 mice 
brains. Inclusions were observed in different regions of the CNS including the pontine 
nuclei, lateral reticular nucleus, deep cerebellar nuclei, as well as in non-affected 
regions such as ventral tenia tecta and olfactory anterior nuclei (Silva-Fernandes et al, 
submitted for publication). This is concordant with what is been seen in human MJD 
patients where neurodegeneration is not clearly correlated with the occurrence of ataxin-
3 immunopositive inclusions (Rüb et al, 2006). 
 
 
 
 
Figure 3. Summary of behaviour and pathology findings in CMVMJD135. The dotted lines 
indicate unknown age of initiation of atrophic hyperchromatic neurons in pontine and 
astrogliosis in substantia nigra as well muscle atrophy.    
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2. OBJECTIVES 
 
 
 Taking into account the results observed in animals models for MJD it seems 
that neuronal cell death could be a final stage after a long period of neuronal 
dysfunction. In this manner, neuronal cell death observed in post-mortem brain patients 
- whether apoptotic or nonapoptotic - probably occurs when neurons can no longer 
tolerate irreversible and widespread dysfunction of multiple cellular pathways. There is 
a need for the definition of early and late neuropathologic changes in MJD as hallmarks 
that we can use to assess the efficacy of therapeutic compounds, in addition to the 
behavioural endpoints (neurological function tests) in animal models of 
neurodegenerative disease. 
 
 
Thus, the objectives of this work were: 
 
i) To determine the volumes of brain regions affected in MJD in the CMVMJD135 
mouse model: pontine nuclei, substantia nigra, locus coeruleus and dentate nuclei, and 
to assess the cerebellar cortex (molecular and granular) layer thickness rather than 
volume. 
 
ii) To quantify the number of cells in the brain regions with volume alteration in the 
previous task. 
 
iii) To evaluate the type of cells which are quantitatively altered (astrocytes or neurons) 
when the total cell number was altered. 
 
  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
    3. MATERIAL AND METHODS 
 
 
  
 
3. MATERIAL AND METHODS 
29 
 
3.1. Animals 
 
 All animals were maintained under standard laboratory conditions: an artiﬁcial 
12 h light/dark cycle (lights on from 8:00 to 20:00 h), with an ambient temperature of 
21± 1 °C and a relative humidity of 50–60%; the mice were given a standard diet 
(4RF25 during the gestation and postnatal periods, and 4RF21 after weaning, Mucedola 
SRL, Settimo Milanese, Italy) and water ad libitum. Health monitoring was performed 
according to FELASA (Federation for laboratory animal science associations) 
guidelines (Nicklas et al, 2002), conﬁrming the Speciﬁed Pathogen Free health status of 
sentinel animals maintained in the same animal room. All procedures were conducted in 
accordance with European regulations (European Union Directive 86/609/EEC). 
Animal facilities and the people directly involved in animal experiments were certiﬁed 
by the Portuguese regulatory entity — Direcção Geral de Veterinária. All of the 
protocols performed were approved by the joint Animal Ethics Committee of the Life 
and Health Sciences Research Institute, University of Minho, and the Institute for 
Molecular and Cell Biology, University of Porto. 
 
3.2. DNA extraction and mouse genotyping  
 
 
 DNA from mouse tail biopsy (~5 mm) was isolated using a Citogene Kit 
(Citomed). Tails were digested overnight with 300µL of Cell Lysis buffer (Citogene 
Kit, Citomed) and 2µL of Proteinase K (Citogene). Then we added 100 µL of protein 
precipitation solution (Citogen Kit, Citomed), vortexed for 20 seconds followed by a 
centrifugation at 13000 rpm during 8 minutes. The supernatant was suspended in 300 
µL of isopropanol and then centrifuged again at 13000 rpm during 8 minutes. The 
pellets were washed in 70% ethanol and centrifuged at 13000 rpm for 2 minutes. The 
pellets were eluted in 30 µL DNA Hydration solution (Citogene Kit, Citomed). 
 In a single PCR genotyping tube we used 6,25 µL of Supreme Master Mix 2x 
Green (NZYTaq, NZYTech), 1µL of the primers TR6 (5’-TACATCAATGGGCGT 
GGAT-3) and TR7 (5’-GAGGTCAAAACAGCGTGGA-3’) at the concentration of 10 
µM to amplify the transgene (454 bp), and 0,5 µL of the primer mmMJD89 (5’-
GCTAGCTAGAGCTACTTATTG-3’) and mmMJD54 (5’-GACTCCAGAGAGCAC 
CTG-3’) at the concentration of 10 µM to amplify the mouse homologous ATXN3 gene 
3. MATERIAL AND METHODS 
30 
 
(800 bp) as an internal control of the PCR. The DNA was added at a concentration of 
100ng/uL. The PCR conditions were as follows: 95ºC, for 10 minutes, 35 cycles: 1 
minute of denaturation step at 95ºC, annealing at 60ºC and elongation at 72ºC. The final 
elongation was at 72ºC for 5 minutes. The PCR product was hold at 4ºC.  
 Amplification products were visualized in 1,5% (W/V) agarose gel and 
electrophoresed at 120 Volts for 20 minuts. Gels were analysed in Gel Doc 
TM 
EZ 
Imager (BIO RAD) by the Image Lab 
TM 
Software version 4.1.  
 
3.3. Molecular analysis of the (CAG)n repeat 
 
 In a single tube, 2,5 µL of 10x High Fidelity PCR Buffer + MgCl2 (Fermentas), 
0,4µL of 10mM dNTP’s (NZYTech), 0,5 µL of the primer MJD25a at the concentration 
of 6,6 ng/µL (5′-GGCTGGCCTTTCACATGGAT-3′ ), 0,5 µL 6-FAM fluorescently-
labeled MJDcDNA primer at 6,6ng/µL (5′-CGGAAGAGACGAGAAGCCTAC-3′), 
1,25 µL of DMSO 100% and 0,2 µL of Taq High Fidelity enzyme (Fermentas). The 
genomic DNA was used at a concentration of 25ng/µL. The PCR parameters were as 
follow: 95ºC, for 10 minutes, 35 cycles: 1 minute of denaturation step at 95ºC, 
annealing at 60ºC and elongation at 72ºC. The final elongation was at 72ºC for 5 
minutes. The PCR product was hold at 4ºC.  Amplification products were visualized in 
1,5% (W/V) agarose gel electrophoresis and gels were analysed in Gel Doc 
TM 
EZ 
Imager (BIO RAD) by the Image Lab 
TM 
Software version 4.1.  
 Products were displayed in an ABI 310 automated DNA sequencer (Applied 
Biosystems, Foster City, CA). The major allele size was determined by densitometry 
using AlphaEase software  to detect the peak with the highest height in the AlphaImager 
2200 (AlphaInnotech). The CAG tract length of the major size band was determined 
using an equation from the calibration curve obtained with cloned alleles containing 
known numbers of CAG repeats (Williams et al, 1999). 
 
3.4. Stereology 
 
 3.4.1. Tissue preparation and staining 
 
 At 60 weeks of age, CMVMJD135 (n=9) and wild-type (n=6) mice were deeply 
anaesthetized: ketamine hydrochloride (150 mg/kg) plus medetomidine (0,3 mg/kg); 
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and transcardially perfused with 4% paraformaldehyde (PFA) in phosphate buffered 
saline (PBS). The brains were removed, blocked in the coronal plane and processed in 
glycomethacrylate (Tecnovit 7100). Approximately 4 weeks post-processing, brains 
were sectioned at 30 µm in the coronal plane with a rotating microtome and wet 
mounted on gelatinized slides. The sections were stained with 10% Giemsa stain, 
mounted with Entellan-New (Merck) and coverslipped.  
 
 3.4.2. Design-based stereology 
 
 Design-based stereological estimates of neuronal number and regional volume 
were obtained by systematic random sampling in pontine nuclei (Bregma level - 3.80 
mm through - 4.60 mm), substantia nigra (Bregma level - 2.46 mm through - 4.04 mm), 
dentate nuclei (Bregma level - 5.68 mm through - 6.36 mm) and locus coerulerus 
(Bregma level - 5.34 mm through - 5.80 mm) according to the Paxinos and Franklin 
mouse brain atlas of 2001. The above-mentioned regions were outlined based on 
noticeable citoarchitectural differences, namely density of cells. Stereological 
procedures were performed blind to the observer. 
 
 3.4.3. Cavalieri’s principle: Volume estimation 
 
 The Cavalieri’s method was used to assess the volume of regions of interest. The 
Cavalieri’s principal permits an unbiased and accurate volume evaluation of an arbitrary 
shape and size three-dimensional structure using two-dimensional serial-sections. 
Estimates of regional volume were obtained based on systematic random point counting 
(Gundersen and Jensen, 1987). Briefly, every 2 sections were used and the cross-
sectional area was estimated by point counting (final magnification 40x). The volume of 
regions of interest was estimated by counting the number of unique points along a 
systematic random grid, across the outlined region that fell within the region of interest. 
Each included point represents a known area, such that the sum of the number of points 
lying within the boundaries of the region multiplied by the corresponding area and also 
multiplied by the represented thickness yields an estimate of the volume for each animal 
in cubic microns. Thus, multiplying the distance between sections by their total cross-
sectional area give us a volume that leads to precise MRI-like results.  
 A 
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 Measurements were performed using the Visiopharm Integrator System, version 
2.12.3.0 and a camera (Pixelink PL – A622) attached to a motorized microscope 
(Olympus BX51) using a 40X, 0.16 numerical aperture oil immersion objective. 
 
  3.4.4. Fractionator: neuronal number estimation 
 
 Average cell number was estimated using the optical fractionator method. The 
optical fractionator is a combination of the optical dissector, a three-dimensional probe 
used for counting, and fractionator sampling a scheme involving the probing of a known 
fraction of tissue (West et al, 1991). Three sampling fractions are used with the optical 
fractionator method. First, the section sampling fraction (ssf) represents the proportion 
of microscopical sections of the entire, serially sectioned brain structure that is sampled 
for evaluation. The area sampling fraction (asf) corresponds to the proportion of the 
sectional area that is investigated within the sampled sections. And, finally, the height 
(h) of the dissector is known relative to the thickness of the sections (t) and captures the 
part of the investigated cross-sectional area of the sampled sections. The estimated total 
number of particules (N) is obtained by multiplying the total number of cells actually 
counted in the dissectors ( ∑Q - ) that fell within the sectional profiles of the subdivision 
seen in the sampled sections per brain structure (figure 4) (West et al, 1991). 
 
      
 
   
 
 
   
 
 
 
 
 
Figure 4. Formula of estimation of the total number of cells (West et al, 1991). 
 
 The size of the region of interest is implicitly determined from the combination 
of these fractions. This means that, with the optical fractionator technique, no 
information on the size of the region of interest or magnification of the microscope is 
needed. This also implies that this counting technique is independent of e.g. swelling 
and/or shrinkage of the tissue during processing (West, 1993).  
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In summary, a grid of virtual 3D-boxes equally spaced was superimposed on every 2th 
section of interest and we counted the number of cells falling inside it (figure 5).  
 
 
Figure 5. Counting frame of the optical dissector. An object is counted if it lies completely 
inside the counting frame or if it crosses a green (inclusion) line but not a red (exclusion) line. 
(adapted from: http://www.stereology.info/criteria-for-counting-cells/) 
 
 
 Inclusion and exclusion counting criteria were followed by a blinded observer 
who recorded counts only when a single cell nucleolus was brought into focus within 
the dissector frame (Sterio, 1984).  
 In this study, every second section containing the pontine nuclei, substantia 
nigra, locus coeruleus and dentate nuclei was selected to obtain a sample in a systematic 
uniform random manner (section sampling fraction; ssf=0.5).  
- For pontine nuclei and substantia nigra: The area (a) of the counting frame 
was 400 μm² (20 μm×20 μm), the area sampling fraction (asf) = a (frame)/ a 
(step length) was 0,004. The height (h) of the optical dissector was 15µm. The 
yielding for pontine nuclei was 10-13 sections per brain and for substantia nigra 
was 18-22 sections per brain. 
 
- For locus coeruleus: The area (a) of the counting frame was 400 μm² (20 
μm×20 μm), the area sampling fraction (asf)= a (frame)/ a (step length) was 
0,04. The height (h) of the optical dissector was 15µm. The yielding was 5-7 
sections per brain. 
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- For dentate nuclei: The area (a) of the counting frame was 400 μm² (20 μm×20 
μm), the area sampling fraction (asf)= a (frame)/ a (step length) was 0,018. The 
height (h) of the optical dissector was 15 µm. The yielding was 9-11 sections per 
brain. 
 
The quantification of the total cell number was performed using The Visiopharm 
Integrator System, version 2.12.3.0 and a camera (Pixelink PL- A622) attached to a 
motorized microscope (Olympus BX51) using a 400X, 1.0 numerical aperture oil 
immersion objective. 
 
3.5. Immunohistochemistry 
 
 
 CMVMJD135 transgenic (n=9) and wild-type mice (n=6) with 93 weeks of age 
were deeply anaesthetized (3mL Imalgène, 600µL Dorvet and 19,5 mL saline) and 
transcardially perfused with 4% PFA in PBS. Brains were post-ﬁxed overnight in 
ﬁxative solution and embedded in parafﬁn. Representative sections of mice brains were 
stained with hematoxylin-eosin (H&E) for histological examination. For IHC, slides 
with 4-µm-thick sections were placed in the incubator at 72ºC for 10 minutes to allow 
the paraffin to melt and then we proceed with the deparaffinization/ hydration protocol. 
10mM citrate buffer, pH=6.0 was pre-heated and slides were incubated  in the buffer 
during 20 minutes in the microwaves, at low temperature, in order to allow the antigen 
retrieviel. After that, slides were transferred to dH2O for 15 minutes and endogenous 
peroxidase was inactivated by immersing the tissue sections in 3% H2O2 in PBS 
solution for 30 min. Slides were then washed in PBS and PBS-Triton 0,3% and the 
blocking was performed using V Block solution (Ultravision Plus large volume 
detection system Anti-polivalent, HRP-Thermo scientific), during 8 minutes. 
- For NeuN (Neuronal Nuclei) staining in pontine nuclei, slides were incubated 
with mouse monoclonal antibodies against neuronal nuclei, NeuN (Chemicon, 
Millipore) (1:100). 
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- For GFAP (Glial Fibrilary Acidic Protein) staining in pontine nuclei, slides were 
incubated with polyclonal rabbit GFAP antibody (DAKO Corporation, 
Carpinteria, CA) (1:500). 
 
- For TH (Tyrosine-Hydroxylase) staining in substantia nigra, slides were 
incubated with polyclonal rabbit TH antibody (Chemicon, Milipore) (1:300). 
 
 
 A biotinylated secondary antibody was applied, followed by the streptavidin-
biotin peroxidase complex system (Ultra Vision Large Volume Detection System Anti-
Polyvalent, HRP; Lab Vision Corporation, Fremont, CA, USA) according to the 
manufacturer's instructions and with peroxidase-diaminobenzadine to visualize and 
develop the antigen-antibody reaction and DAB (3,3-diaminobenzidine) substrate 
(Vector Laboratories Inc., Burlingame, CA, USA). The slides were counterstained with 
hematoxylin 25% according to standard procedures and analysed with an optical 
microscope (Olympus, Hamburg, Germany). Finally, they were mounted with Entellan-
New (Merck) and coverslipped. 
 The stereological analysis of GFAP and NeuN positive cells in pontine 
nuclei and the estimate of TH-positive neurons in substantia nigra (total 3 sections per 
brain) was performed in sagittal sections using The Visiopharm Integrator System, 
version 2.12.3.0 and a camera (Pixelink PL- A622) attached to a motorized microscope 
(Olympus BX51) using a  400X, 1.0 numerical aperture oil immersion objective.  
 
3.6. Estimation of cerebellar layer thickness 
 
 
 Paraffin-embedded sagittal sections were stained with hematoxylin and eosin 
(H&E) and the thickness of molecular and granular layers of the cerebellum were 
measured at preculminate fissure (PCFUF) and secondary fissure (SF) in 6 animals (n=3 
CMVMJD135 and n=3 wild-type) at 93 weeks of age. One rectangular line was drawn 
across PCFUF and SF, and 3 perpendicular lines (distant from each other 200 µm) were 
drawn in order to measure the thickness of the layers. The measurements of each layer 
for each animal were averaged. Two sections were measured per animal (figure 6). 
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Figure 6. Measurements of molecular and granular layers of cerebellum in secondary fissure.  
 
3.7. Statistical analysis 
  
  
 Continuous variables with normal distribution (K-S test p>0.05) were analysed 
with the Student t-test. All statistical analyses were performed using SPSS 20.0 and a 
critical value for significance of p< 0.05 was used throughout the study. 
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4.1. Quantification of volume and total number of cells in brain regions 
known to be affected in MJD. 
 
 
 In this chapter we quantified the total number of cells and determined the 
volume in the pontine nuclei, locus coeruleus, substantia nigra and dentate nuclei in 
CMVMJD135 transgenic animals at 60 weeks of age and their wild-type littermates. At 
this age, CMVMJD135 mice exhibit a well established phenotype characterized by 
severe motor deficits such as balance deficit, gait ataxia and motor uncoordination. 
They also present brain pathology characterized by the presence of ataxin-3-positive 
intranuclear inclusions in several brain regions, namely in the pontine and dentate nuclei 
(Silva-Fernandes et al, submitted for publication). 
 Moreover, the analysis of the CAG repeat length of CMVMJD135 mice revealed 
no variations among animals (average of CAG repeat: 133±1.86). 
 
 
 4.1.1. Pontine nuclei 
 
 The pontine nuclei (PN) are a part of the pons involved in motor activity.  They 
allow modification of actions in the light of their outcome, or error correction, and are 
hence important in learning motor skills. Afferent fibers entering the cerebellum via the 
middle cerebellar peduncle contain afferents from the cerebral cortex that synapse in the 
pons. In pons, pontine nuclei project to the opposite side of the cerebellum via the 
crossed fibers of the middle cerebral peduncle. Forming the largest of the afferent fibers 
to the cerebellum, the middle cerebellar fibers enter the cerebellum where each axon 
branches to innervate granule cells. This connection forms the main pathway linking the 
cerebral cortex to the cerebellum (figure 7) (Bhatnagar, 2002). 
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Figure 7. Illustration of cortico-pontine (PN)-cerebellar pathway. The red arrows correspond to 
cerebellar afferent system (corticopontine and pontocerebellar tracts). The grey arrows 
correspond to efferent cerebellar projections. 
 
 
Figure 8. Low magnification micrograph of glycolmethacrylate-embedded coronal section of 
pontine nuclei of the mouse stained with Giemsa and the corresponding atlas scheme used for 
delineation of the region. 
 
 In order to assess the volume and total number of cells in pontine nuclei, we 
performed stereological analysis in 5 wild-type animals and 9 CMVMJD135 transgenic 
animals. Our results revealed a 13% decrease in volume (p=0.018) and 12% decrease in 
total number of cells (p=0,032) in pontine nuclei of CMVMJD135 mice when compared 
to wild-type animals. 
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Figure 9. Total volume (A) and total number of cells (B) of pontine nuclei calculated for wild-
type (♂ n=5) and CMVMJD135 mice (♂ n=9). Asterisks indicate significant differences 
between wild-type and CMVMJD135 mice (*p<0.05). CMVMJD135 showed a loss of volume 
(13%) and decrease in the number of cells (12%) in pontine nuclei. 
 
 
 4.1.2. Locus coeruleus 
 
 The locus coeruleus is located in the posterior area of the rostral pons in the 
lateral floor of the fourth ventricle. It is composed of mostly medium-size neurons 
(Berridge and Waterhouse, 2003). Melanin granules inside the neurons of locus 
coeruleus contribute to its blue color. Locus coeruleus is the principal site for brain 
synthesis of norapinephrine (noradrenaline). The locus coeruleus and the areas of the 
body affected by the norepinephrine that it produces are described collectively as 
the locus coeruleus-noradrenergic system (LC-NA system) (Mehler and Purpura, 2009). 
The projections of this nucleus reach far and wide. They innervate the spinal cord, the 
brainstem, cerebellum, hypothalamus, thalamus, the basal telencephalon and 
the cerebral cortex (figure 10) (Bhatnagar, 2002). 
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Figure 10. Illustration of the locus coeruleus (LC) – noradrenergic system. The red 
arrows correspond to the main brain regions involved in the noradrenergic system. 
 
 Some of the most important functions influenced by locus coeruleus are
 
neuroplasticity, arousal and sleep-wake cycle, attention and memory, emotions, 
behavioural flexibility, behaviour inhibition and stress, posture and balance (Benarroch, 
2009). 
 
 
 
Figure 11. Low magnification micrograph of glycolmethacrylate-embedded coronal section of 
locus coeruleus of mouse stained with Giemsa and the corresponding atlas scheme used for 
delineation of the region. 
 
 In order to assess the volume and total number of cells in the locus coeruleus, we 
performed stereological analysis in 5 wild-type mice and 5 CMVMJD135 animals. Our 
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results revealed a non-significant trend towards a reduction of the volume and total 
number of cells in CMVMJD135 mice when compared to wild-type animals. 
 
 
 
 
 
 
 
 
 
Figure 12. Total volume (A) and total number of cells (B) of locus coeruleus calculated for 
wild-type (♂ n=5) and CMVMJD135 mice (♂ n=5). CMVMJD135 showed a trend towards a 
decrease, although not statistically significant, in volume and in the total number of cells in 
locus coeruleus. 
 
 
 4.1.3. Substantia nigra 
 
 The substantia nigra is a brain structure located in the mesencephalon (midbrain) 
that plays an important role in reward, addiction and movement. The substantia nigra is 
a large motor nucleus located between the tegmentum and the crus cerebri, and is found 
throughout the midbrain. The nucleus is composed of medium-size multipolar neurons 
that possess inclusion granules of melanin pigment within their cytoplasm. The neurons 
of the substantia nigra are dopaminergic and inhibitory and have many connections to 
the striatum. It projects axons to the caudate nucleus and the putamen and release 
dopamine at their terminals as the neurotransmitter (Snell, 2010). Substantia nigra 
makes part of the main basal ganglia loop which includes other brain areas such as the 
striatum (caudate nucleus and putamen), globus pallidus and the subthalamic nucleus 
(figure 13) (Bhatnagar, 2002). 
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Figure 13. Illustration of the major basal ganglia loop. The red arrows  correspond to the 
principal afferent and efferent fibers forming basal ganglia loops; it  incudes the dopaminergic 
projections from substantia nigra (SN) to caudate/putamen. 
 
 Although the substantia nigra appears as a continuous band in brain sections, it 
actually consists of two parts with very different connections and functions: the pars 
compacta and pars reticulata. The pars compacta serves mainly as an input to the basal 
ganglia circuit, supplying the striatum with dopamine. The pars reticulata, on the other 
hand, serves mainly as an output, conveying signals to the thalamus and superior 
colliculus (Deniau et al, 1978). 
 
 
 
 
Figure 14. Low magnification micrographs of glycolmethacrylate-embedded coronal section of 
substantia nigra of the mouse stained with Giemsa and the corresponding atlas scheme used for 
delineation of the region. 
4. RESULTS 
45 
 
 
 In order to assess the volume and total number of cells in substantia nigra, we 
performed stereological analysis in 5 wild-type animals and 5 CMVMJD135 mice. Our 
results revealed no differences in terms of volume and total number of cells in 
substantia nigra of CMVMJD135 mice when compared to the wild-type control 
animals. 
 
 
 
 
 
 
 
 
 
Figure 15.  Total volume (A) and total number of cells (B) of substantia nigra calculated for 
wild-type (♂ n=5) and CMVMJD135 mice (♂ n=5). CMVMJD135 didn’t show differences in 
terms of volume and total number of cells in substantia nigra. 
 
  
 4.1.4. Dentate nuclei 
  
 The dentate nuclei are located within the deep white matter of each cerebellar 
hemisphere, and are the largest structures linking the cerebellum to the rest of the brain 
(Snell, 2010). The dentate nuclei are responsible for the planning, initiation and control 
of voluntary movements. Dentate nuclei receive afferent signals from the motor cortex 
via the pontocerebellar system and efferent signals via the superior cerebellar 
peduncle through the red nucleus to the contralateral and ventrolateral thalamus (figure 
16) (Bhatnagar, 2002). The dorsal region of the dentate nuclei contains output channels 
involved in motor function, more specifically the movement of skeletal muscle, while 
the ventral region contains output channels involved in non motor functions, such as 
conscious thought and visuospatial function (Sultan, 2010). 
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Figure 16. Illustration of the dentato(rubro)thalamocortical pathway. The red arrows represent 
efferent projections of cerebellum that arise from dentate nuclei (DN) and continue their way to 
the motor cortex. Grey arrows correspond to the major afferent pathway of cerebellum. 
 
 
 
 
Figure 17. Low magnification micrographs of glycolmethacrylate-embedded coronal section of 
dentate nuclei of the mouse stained with Giemsa and the corresponding atlas scheme used for 
delineation of the region. 
 
 In order to assess the volume and total number of cells in dentate nuclei, we 
performed stereological analysis in 4 wild-type mice and 4 CMVMJD135 transgenic 
mice. No statistically significant differences were observed in terms of total number of 
cells in this region. However, our results revealed a decrease of 37% in volume of 
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dentate nuclei (p=0,0062) of CMVMJD135 mice when compared to the wild-type 
animals. 
 
 
 
 
 
 
 
 
 
 
Figure 18. Total volume (A) and total number of cells (B) of dentate nuclei calculated for wild-
type (♂ n=4) and CMVMJD135 mice (♂ n=4). Asterisks indicate significant differences 
between wild-type control and CMVMJD135 transgenic mice (**p<0.01). CMVMJD135 
showed a loss of volume (37%) in dentate nuclei and a non-significant decrease in the total 
number of cells. 
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4.2. Quantification of specific cell types – neurons and astrocytes – in 
CMVJD135 mouse brains. 
 
 Although extremely complex, the brain is largely constituted of only two main 
cell types: neurons and glial cells. 
 Neurons are involved in information transmission – receiving, processing and 
transmitting information through their highly specialised structure. The majority of 
neurons are unable to undergo cell division or repair (Snell, 2010). NeuN is a 
neuronal nuclear antigen that is commonly used as a biomarker for neurons. NeuN 
immunoreactivity has been widely used to identify neurons in tissue culture and in 
sections and to measure the neuron/glia ratio in brain regions (Herculano-Houzel and 
Lent, 2005). 
 Glial cells are major constituents of the CNS, and while they do not have a direct 
role in neurotransmission, they play a supporting role that helps define synaptic contacts 
and maintain the signalling abilities of neurons. Various types of glial cells can be found 
in the brain; including astrocytes, oligodendroglia and microglia. Glial cells are smaller 
than neurons and they have well-defined roles such as modulating the rate of nerve 
impulse propagation; controlling the uptake of neurotransmitters; and playing a pivotal 
role during development and adulthood (Snell, 2000). Glial fibrillary acidic protein 
(GFAP) is an intermediate filament (IF) protein that is expressed by numerous cell types 
of CNS, including astrocytes, astrogliosis being characterized by a rapid increase in the 
synthesis of GFAP intermediate filaments (Eng et al, 2000). 
 In this chapter we aimed to determine which type of cells are quantitatively 
altered in regions that presented altered number of cells (previous results). Thus, we 
performed IHC in order to stain for neurons (IHC anti-NeuN) and astrocytes (IHC anti-
GFAP) in the pontine nuclei of CMVMJD135 transgenic animals at 93 weeks of age 
and compared with wild-type animals.  
 
Our results revealed no differences in the number of GFAP-positive cells in 
pontine nucleus of CMVMJD135 mice when compared to wild-type animals (Figure 
19). Interestingly, CMVMJD135 mice showed a reduced number, albeit not statistically 
significant, of NeuN-positive cells in the pontine nuclei (Figure 20). 
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Figure 19. GFAP immunostaining of the pontine nuclei in CMVMJD135 (♂ n=5) (A-B) and 
wild-type (♂ n=3) animals (C-D) at late stage of the disease (93 weeks of age); Scale bar: 50 
µm (A and C) and 20 µm (B and D) and the quantification of the number of GFAP-positive 
cells calculated for wild-type and CMVMJD135 mice in pontine nuclei (E). CMVMJD135 
showed no significant differences in the number of astrocytes. 
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Figure 20. NeuN immunostaining of the pontine nuclei in CMVMJD135 (♂ n=4) (A-B) and 
wild-type (♂ n=3) animals (C-D) at late stage of the disease (93 weeks of age). Scale bar: 50 
µm (A and C) and 20 µm (B and D); and the quantification of the number of NeuN-positive 
cells calculated for wild-type and CMVMJD135 mice in pontine nuclei (E). CMVMJD135 
showed a trend towards decrease in the number of neurons, although not statistically significant. 
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 4.2.1. Quantification of dopaminergic neurons in the substantia 
nigra.  
 
 Dopamine is a simple organic chemical in the catecholamine and 
phenethylamine families that plays a number of important roles in the brain. Inside the 
brain, dopamine functions as a neurotransmitter plays an important role in motor control 
and motivation. Dopaminergic neurons are neurons whose primary neurotransmitter is 
dopamine (Schultz, 2007). These neurons are confined to a few relatively small brain 
areas such as substantia nigra, however, they send projections to many other brain areas 
and exert powerful effects on their targets (Björklund and Dunnett, 2007). The 
degeneration of the neurons of the substantia nigra that send their axons to the corpus 
striatum results in a reduction in the release of the neurotransmitter dopamine within the 
corpus striatum. This leads to hypersensitivity of the dopamine receptors in the 
postsynaptic neurons in the striatum (Snell, 2000).  
 Tyrosine hydroxylase is the enzyme responsible for catalyzing the conversion of 
the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) (Kaufman, 
1995). Since L-DOPA is the precursor for the neurotransmitter dopamine, we can assess 
dopaminergic neurons levels in substantia nigra by quantifying the tyrosine hydroxylase 
– immunopositive cells (Goti et al, 2004). 
 
 In this part of the work, we aimed to quantify the dopaminergic neurons in 
substantia nigra of CMVMJD135 and further compare the results with wild-type 
animals. For that, we performed immunohistochemistry anti-TH and quantified the TH-
positive cells in substantia nigra of transgenic (n=4) and wild-type (n=3) animals at 93 
weeks of age. 
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Figure 21. Tyrosine-hydroxylase (TH) immunostaining in substantia nigra in CMVMJD135 (A-C) and wild-type animals (D-F) at late stage of the disease (93 
weeks of age). Scale bar: 200 µm (A and D) 50 µm (B and E) and 20 µm (C and F). 
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 Our results demonstrate that CMVMJD135 transgenic mouse model have a statistically 
significant decrease of 28% of dopaminergic neurons in substantia nigra pars compacta when 
compared to wild-type animals (p=0,0005). 
 
 
 
 
 
 
 
 
 
Figure 22. Number of TH-positive cells calculated for wild-type (♂ n=3) and CMVMJD135 
mice (♂ n=4) in substantia nigra. Asterisks indicate significant differences between wild-type 
control and CMVMJD135 transgenic mice (***p<0.001). CMVMJD135 showed a statistically 
significant decrease in the number of dopaminergic neurons (28%) in substantia nigra pars 
compacta. 
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4.3. Analysis of cerebellar layer thickness in CMVMJD135 
 
 
 The cerebellum is a region of the brain that plays an important role in motor 
control. Cerebellum contributes to coordination, precision, and accurate timing. It 
receives input from sensory systems of the spinal cord and from other parts of the brain, 
and integrates these inputs to fine tune motor activity (Fine et al, 2002). The cerebellum 
is located at the bottom of the brain and like the cerebral cortex, it is divided into two 
hemispheres. A set of large folds are conventionally used to divide the overall structure 
into ten smaller lobules layers. Because of its large number of tiny granule cells, the 
cerebellum contains more neurons than the rest of the brain put together (Snell, 2000). 
 There are three layers to the cerebellar cortex: the molecular, Purkinje, and 
granular. The innermost layer (granular) contains the cell bodies of two types of cells: 
the granule cells and the the Golgi cells. Mossy fibers enter the granular layer from their 
main point of origin, the pontine nuclei. These fibers form excitatory synapses with the 
granule cells and the cells of the deep cerebellar nuclei.  Golgi cells provide inhibitory 
feedback to granule cells, forming a synapse with them and projecting an axon into the 
molecular layer. The middle layer (Purkinje) contains only one type of cells— Purkinje 
cells. These cells are the primary integrative neurons of the cerebellar cortex and 
provide its sole output. Purkinje cell dendrites are large arbors with hundreds of spiny 
branches reaching up into the molecular layer. Purkinje neurons are GABAergic - 
meaning they have inhibitory synapses - with the neurons of the deep cerebellar and 
vestibular nuclei in the brainstem. The outermost layer (molecular) of the cerebellar 
cortex contains two types of inhibitory interneurons: the stellate and basket cells. It also 
contains the dendritic arbors of Purkinje neurons and parallel fiber tracts from the 
granule cells. Both stellate and basket cells form GABAergic synapses onto Purkinje 
cell dendrites (Voogd and Glickstein, 1998). 
 
 In this part of the work, we aimed to measure the thickness of molecular and 
granular layers of the cerebellum in CMVMJD135 and compare the values with wild-
type animals. In order to do that, we analysed the thickness of these layers in transgenic 
(n=3) and wild-type (n=3) animals at 93 weeks of age. 
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Figure 23. Low magnification micrograph of a sagittal section of cerebellum of the mouse 
stained with H&E and the corresponding atlas scheme used for the identification of the 
preculminate fissure (pcuf) and secondary fissure (sf). 
 
 Our results revealed a statistically significant (p=0,044) decrease of 10% of the  
thickness of the molecular layer in CMVMJD135 compared to the wild-type animals. 
However, no statistically significant differences were observed in the granular layer. 
 
 
Figure 24. Measurements of molecular (A) and granular (B) layers of cerebellum calculated for 
wild-type (♂ n=3) and CMVMJD135 mice (♂ n=3). Asterisks indicate significant differences 
between wild-type control and CMVMJD135 transgenic mice (*p<0.05). CMVMJD135 
showed a statistically significant decrease in the thickness of molecular layer. No differences 
were found in the granular layer. 
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5. DISCUSSION 
 
   
 Recently, our team generated a transgenic mouse model of MJD, CMVMJD135, 
that shows severe symptoms of the disease including balance deficits, motor 
uncoordination and weight loss, that appear and progress overtime. Taking into account 
that this mouse model presents severe symptoms of the disease we aimed to characterize 
the neuropathologic features, by performing stereological analysis in a selection of brain 
areas known to be affected in MJD patients, such as the substantia nigra in the 
midbrain (mesencephalon), the pontine nuclei in ventral pons, the locus coeruleus in the 
rostral pons (metencephalon) and dentate nuclei in the cerebellum. All of these regions 
play an important role in motor activity, which is compromised in MJD patients. 
 In this work, we performed stereological analyses in pontine nuclei and we 
found a loss of volume of 13% in our transgenic mice. Furthermore, we aim to clarify 
the basis of this volume reduction, so we quantified the total number of cells and we 
found a significant decrease of 12% in the cell number in the pontine nucleus. This 
reduction of cells is in the same proportion to that observed in the volume, so we could 
conclude that this reduction of volume was actually caused by a loss of cells. In order to 
better understand which type of cells was decreased, neurons or glial cells, we evaluated 
differentially, the number of each type of cells (astrocytes and neurons) in 
CMVMJD135 mice and compared the values with wild-type animals. We did not 
observe differences in the number of astrocytes; however, we were able to see a 
decrease, although not statistically significant, of the neurons number in pontine nuclei 
of CMVMJD135 mice. One possible explanation of this result owns to the fact that the 
reduction of volume and the reduction of the cell number are very similar suggesting 
that the cell density (number of cells/ area) trends to be the same independently of the 
dimension of the region. In order to confirm the trend towards a reduction in the total 
cell number, we should increase the number of animals in the study. Overall, the results 
observed in pontine nuclei are concordant with those found in MJD human patients, 
since mild to moderate neuronal loss is detected in the pontine nucleus of MJD patients 
(Yamada et al, 2008). Neuronal cell loss, although assessed by a non-specific 
quantification method, was previously reported in the pontine nuclei of MJD84.2 mouse 
model (Cemal et al, 2002). Signals of abnormal morphology of neurons were also 
described by the presence of hyperchromatic and shrunken scattered dark cells with 
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pyknotic nuclei and eosinophilic cytoplasm in pontine nuclei of several mouse models, 
including our CMVMJD135 transgenic mice (Cemal et al, 2002; Silva-Fernandes et al, 
2010; Silva-Fernades et al, article submitted for publication).  
 The stereological analysis of locus coeruleus revealed a non-significant trend 
towards decrease in the volume as well as in the total number of cells. It is possible that 
CMVMJD135 do not have alterations in volume and cell number in this region, 
however to be more clear about this fact we should increase the number of animals used 
in the experiment, in order to reduce the individual variability observed in each group, 
which by itself generates an increased standard deviation that decreases the statistically 
significance of the results. On the other hand, this mouse model may have a slight, but 
not a severe atrophy of this region, or even a neuronal dysfunction that does not 
culminated in neuronal loss. Locus coeruleus is an affected brain region in MJD 
patients, who present loss of pigment and moderate neuronal loss of this region (Muñoz 
et al, 2002). However, so far no neuropathologic studies of the locus coeruleus have 
been described in the mouse models generated for MJD. 
 In order to evaluate the pathology of substantia nigra in our mouse model, we 
performed stereological analysis in this region. We did not observe any differences in 
terms of volume and total number of cells in substantia nigra of CMVMJD135 mice 
compared to wild-type animals. Pathological studies have demonstrated that MJD 
consists of a diffuse neurodegenerative process with a severe neuronal loss in substantia 
nigra (Riess et al, 2008). Our team previously observed increased reactive astrocytes in 
a phenomenon normally associated with neuronal demise in this region of the brain in 
the CMVMJD94 (Silva-Fernandes et al, 2010) as well as in CMVMJD135 (Silva-
Fernandes et al, article submitted for publication). Thus, we decided to quantify the TH-
positive neurons in the substantia nigra pars compacta of the CMVMJD135 mice. Our 
results showed a statistically significant decrease in the number of dopaminergic 
neurons (TH-positive neurons) in substantia nigra pars compacta. Intriguingly, and 
despite this TH-positive cells reduction, we could not observe differences in the volume 
and total cell number in substantia nigra. This might be explained by the subregion 
measured in this brain area. Substantia nigra is constituted by substantia nigra pars 
compacta and pars reticulata. In the stereological study we did not discriminate these 
two subdivisions. We could hypothesise that the substantia nigra pars reticulata might 
not be affected in CMVMJD135, and since it consists of a big part of the substantia 
nigra, we could be masking the results. To overcome this limitation, the stereological 
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measurements should be performed separately. The reduction of dopaminergic neurons 
observed is in concordance with that seen in human MJD patients whose 
neuropathological examination revealed a severe depigmentation of the substantia nigra 
(Rüb et al, 2005). Additionally, significant lower striatal DAT (dopamine transporter) 
density was also observed in patients brains (Braga-Neto et al, 2012). A recent study 
evaluated the correlation between substantia nigra hyperechogenicity with striatal DAT 
uptake in MJD patients and the authors raised the possibility that in MJD there may be 
iron deposition, neuromelanin content decrease, and microglial activation in the 
substatina nigra, leading to its hyperechogenicity, which can be associated with loss of 
presynaptic striatal dopaminergic terminals (Pedroso et al, 2013). Dopaminergic 
neurons are especially vulnerable to damage. The damage of these neurons in the 
substantia nigra results in a Parkinsonian syndrome that can be, although not often, 
found in human MJD patients, being characterized by tremor, hypokinesia, rigidity and 
postural instability (Rosenberg, 1992). Taking into account the mouse models of MJD, 
Goti and co-workers also found a 38% reduction of TH-positive neurons in the 
substantia nigra of MJD transgenic mice, using stereological techniques.  
 In this work we also analysed the volume and total cell number in dentate nuclei 
of the CMVMJD135 transgenic mice and further compare the results with wild-type 
control animals. Our results showed a statistically significant decrease of 37% of the 
volume of this region in CMVMJD135 mice. We did not find differences in the total 
number of cells, suggesting that the decreased volume cannot be explained by a 
decrease in the cell number but probably by the shrinkage of the cells. This 
phenomenon will be further studied by analysing the number of dendrites, their length 
and branching. Studies in MJD patients reveal that the main lesions in MJD are located 
in the spinocerebellar system and cerebellar dentate nuclei (Yamada et al, 2004). 
Previously, Cemal and co-workers reported neuronal loss in dentate nuclei of transgenic 
mouse model of MJD. This group also found increased GFAP staining with a few 
reactive astrocytes in dentate nuclei attributed to neuronal loss and indicative of gliosis 
(Cemal et al, 2002). In 2004, Goti and colleagues reported a stereologic study in dentate 
nuclei of a transgenic mouse model; they observed, although not statistically significant, 
a decrease in the volume of this region (Goti et al, 2004). 
 We also studied the cerebellar morphology in the CMVMJD135 mice. We 
analysed the thickness of molecular and granular layers of cerebellum in our transgenic 
mouse model at very late stage of the disease (93 weeks of age) and we found a 
5. DISCUSSION 
62 
 
reduction of 10% of the molecular layer thickness. This finding is in accordance to what 
seen in MJD human patients at a late stage of the disease. The cerebellum has been 
suggested to be a major target of degenerative processes in MJD (Dürr et al, 1996). The 
cerebellar cortical neurons, however, are preserved in most cases and minimal loss of 
Purkinje cells are encountered in some patients. However, the cerebellar white matter is 
atrophic and shows myelin pallor due to degeneration of the pontocerebellar and 
spinocerebellar fibers (Yamada et al, 2008). Atrophy of molecular, Purkinje and 
granular cell layers is a morphological change seen in terminal clinical stages of 
cerebellar degeneration. Histological analysis performed in brains of some mouse 
models of MJD showed degeneration of all three layers of the cerebellum (Ikeda et al, 
1996) and loss of Purkinje cells (Ikeda et al, 1996; Cemal et al 2002 and Bichelmeier et 
al, 2007). Reactive astrocytes were also reported in cerebellar white matter, which as 
referred before is an indicator of neuronal compromise (Cemal et al, 2002).  
  
 All together these results contribute to a more complete neuropathologic 
characterization of a new mouse model of MJD. These findings can contribute to define 
biomarkers of disease progression and achieve new therapy targets for MJD, in a mouse 
model that presents a severe phenotype of the disease with a neuronal loss pattern 
similar with human MJD patients observed in a late stage of the disease. 
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6. CONCLUSIONS 
  
 
 In this work we performed the neuropathological study of the CMVMJD135 
mice and we observed: 
 
At a late stage of the disease, 
 
- A decrease of 13% of the total volume and 12% of the total cell number in 
pontine nuclei, and no differences in astrocyte and neurons number in this 
region. 
- No differences in the volume and total number of cells in the locus coeruleus. 
- A decrease of 37% of the total volume and no differences in the total cell 
number in the dentate nuclei. 
- No differences in the total volume and total cell number in the substantia 
nigra and a reduction of 28% of dopaminergic neurons number in this region. 
- A decrease of 10% in the thickness of the molecular layer of cerebellum and 
no differences in the granular layer thickness.  
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7. FUTURE PERSPECTIVES 
 
 
 The CMVMJD135 transgenic mouse model shows an important overlap with 
neuropathologic features of MJD (Silva-Fernandes et al, submitted for publication). To 
further complement the study of the neuropathology of the CMVMJD135, we aim to: 
 
- Analyse the morphology of dentate nuclei’s neurons: number of dendrites, their length 
and branching as well as spine density once we observed a volume decrease in dentate 
nuclei that is not related with a decreased cell number. 
 
- Quantify the number of glial cells in the substantia nigra of CMVMJD135 mice, since 
an increased number of these cells was found in a mouse model previously generated in 
our group for MJD, with milder disease. 
 
- Evaluate the volume and total cell number of more CNS regions known to be involved 
in MJD, such as the Clarke’s column in spinal cord, subthalamic nuclei in basal ganglia 
as well as facial nuclei in pons. 
 
- Quantify the noradrenalin transporter (NAT) in the locus coeruleus of CMVMJD135 
mice in order to assess the neuronal function of this region. 
 
- Analyse the projections of substantia nigra to striatum (TH fibers) using the L-cycloid 
optical fractionator software.  
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